title: Effect of raloxifene on serum lipids for type 2 diabetic menopausal women with or without statin treatment.
abstract: OBJECTIVE
  Our aim was to investigate the effect of 1-year treatment with raloxifene, a selective estrogen receptor modulator, on plasma lipid profiles in Japanese postmenopausal type 2 diabetic patients.
  
  
  METHODS
  A total of 43 Japanese women with postmenopausal osteoporosis and type 2 diabetes with serum low-density lipoprotein cholesterol (LDL-C) <3.59 mmol/l, serum triglyceride <1.68 mmol/l and serum high-density lipoprotein cholesterol (HDL-C) >1.03 mmol/l, who took 60 mg/day of raloxifene for 12 months, were enrolled. For analysis, they were divided into 2 groups: nonhyperlipidemia (n = 23) and hyperlipidemia treated with statin (n = 20).
  
  
  RESULTS
  Raloxifene treatment significantly induced a mean reduction in serum LDL-C from 2.90 to 2.36 and 2.67 mmol/l in the nonhyperlipidemia and statin-treated group, respectively. However, the reduction ratio of serum LDL-C showed a significant difference in the nonhyperlipidemia group (17%) compared to the statin-treated group (7%; p = 0.03). Although serum HDL-C showed an increase in both groups (from 1.45 to 1.58 vs. from 1.40 to 1.47 mmol/l), the increase ratio of serum HDL-C was not significant between the two groups. Raloxifene administration showed 15% reduction in the nonhyperlipidemia group (p = 0.02) and 13% reduction in the statin-treated group (p = 0.02) of urinary N-telopeptide of type I collagen. No significant change in blood HbA(1c) was observed in either group.
  
  
  CONCLUSIONS
  The administration of raloxifene to type 2 diabetic women showed favorable efficacy on serum lipid profiles, particularly in patients without statin treatment.
authors.affiliation: Department of Endocrinology and Metabolism, Dokkyo Medical University School of Medicine, Mibu, Japan.
authors.forename: Mihoko
authors.initials: M
authors.lastname: Matsumura
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Monden
authors.forename: Yuki
authors.initials: Y
authors.lastname: Nakatani
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Shimizu
authors.forename: Nozomi
authors.initials: N
authors.lastname: Domeki
authors.forename: Kazunori
authors.initials: K
authors.lastname: Yanagi
authors.forename: Shiori
authors.initials: S
authors.lastname: Ikeda
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Kawagoe
authors.forename: Kikuo
authors.initials: K
authors.lastname: Kasai
mesh_terms: D000368:Aged; D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy; D008593:Menopause; D015663:Osteoporosis, Postmenopausal / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D020849:Raloxifene Hydrochloride / Q000494:pharmacology*
chemical_list: D050071:Bone Density Conservation Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D020849:Raloxifene Hydrochloride